CMAJ OPEN posaconazole prophylaxis. 9 International guidelines now recommend posaconazole as the first-line prophylactic agent in patients with neutropenic acute myeloid leukemia or myelodysplastic syndrome. 10, 11 Fluconazole remains the first-line agent for patients with neutropenia associated with other hematologic malignancies.
The incidence of invasive aspergillosis is influenced by many factors, such as underlying disease, age, type of antifungal prophylaxis used, access to recent diagnostic tools, geoclimatic influences, nosocomial outbreaks and construction activities in and around medical centres. 6, [12] [13] [14] Accordingly, the incidence of probable or proven invasive aspergillosis among patients undergoing treatment for acute myeloid leukemia before the introduction of posaconazole prophylaxis was variable, ranging from 1.0% to 18%. 1, 3, 7, 9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] The effectiveness of such prophylaxis depends on the incidence of the targeted disease at individual centres. 26 Our objective was to retrospectively establish the incidence of invasive aspergillosis at our centre among patients who received remission-induction chemotherapy for acute leukemia to evaluate the potential benefit of primary antimould prophylaxis in high-risk patients with profound neutropenia following intensive chemotherapy.
Methods

Study population and setting
The study was approved by the research ethics committee of the Hôpital Maisonneuve-Rosemont.
We conducted this single-centre retrospective cohort study between January 2008 and December 2010. All adult patients (≥ 18 years of age) with acute myeloid leukemia or acute lymphocytic leukemia who were admitted during the study period for remission-induction chemotherapy were eligible. Patients with a positive result on a galactomannan antigen-detection test at the beginning of chemotherapy were excluded. Our institution, a 588-bed tertiary care hospital built in 1953, is an important referral centre for hematology and hematopoietic stem cell transplantation. Remissioninduction chemotherapy is conducted in protected rooms with positive-pressure, high-efficiency particulate air filtration. Fluconazole was the first-line antifungal prophylactic used during the study period. All patients were screened for serum-circulating galactomannan antigen (with Platelia Aspergillus enzyme immunoassay, Bio-Rad Laboratories, Montréal, Quebec) twice weekly from the start of chemotherapy until bone marrow recovery (defined as absolute neutrophil count > 0.5 × 10 9 /L for 2 consecutive days). If a patient had a positive result on the galactomannan antigendetection test and/or unexplained and persistent (≥ 4 days) febrile neutropenia refractory to broad-spectrum antibiotics, thoracic computed tomography (CT) was performed, followed by fibreoptic bronchoscopy with bronchoalveolar lavage when clinically indicated. In addition to the usual histopathologic analysis and bacterial, viral and fungal culture, bronchoalveolar lavage fluid was subjected to galactomannan antigen-detection testing.
Data collection
We retrieved records from the hospital's central pharmacy database registries for remission-induction chemotherapy regimens prescribed during the study period for patients with acute myeloid leukemia or acute lymphocytic leukemia. We performed a retrospective systematic review of patients' medical charts and computerized hospital databases up to 180 days after resolution of aplasia. We did not exclude patients who received posaconazole prophylaxis during remissioninduction chemotherapy (as part of a clinical trial or for other reasons), because our aim was to determine the true incidence of invasive aspergillosis at our centre. We collected data on demographic characteristics, underlying disease, type of remission-induction chemotherapy, duration of neutropenia, administration of antifungals (for prophylaxis or therapy) and diagnostic procedures, along with any relevant microbiologic, pathologic and radiologic data. We included in our analysis any systemic antifungal therapy administered over the period from initiation of remission-induction chemotherapy to resolution of aplasia.
Definitions and data analysis
We based our definitions of invasive aspergillosis on the 2008 criteria of the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group.27 Only patients with proven or probable invasive aspergillosis were included in the analysis. Briefly, proven cases of invasive aspergillosis required histopathologic or cytopathologic examination showing hyphae from a biopsy specimen, with evidence of associated tissue damage or a positive culture result for a sample obtained from a normally sterile site. Probable cases required an association of host factors, mycologic results (including but not limited to detection of galactomannan antigen and positive culture result for a sample from a nonsterile site) and clinical criteria. The results of serum galactomannan antigendetection testing were considered positive if 2 consecutive serum samples had optical density of 0.5 or higher. For bronchoalveolar lavage fluids, optical density of 2.0 or higher (cutoff established in a local performance study28) was defined as positive. Data were analyzed with descriptive statistics. Categorical variables are expressed as frequencies and percentages, and non-normally distributed continuous variables are expressed as medians with interquartile ranges (IQRs).
Results
From the pharmacy registries, we retrieved remission-induction chemotherapy prescriptions for treatment of acute leukemia in 123 patients. Twenty-two of these patients did not undergo their chemotherapy course and were excluded from the analysis ( Figure 1 ). We analyzed data for a total of 136 courses of remission-induction chemotherapy administered to 101 patients over the 3-year study period ( Table 1 Research CMAJ OPEN first course of remission-induction chemotherapy, usually as part of a clinical trial (4 patients). Fluconazole prophylaxis was prescribed in conjunction with a total of 109 courses (80.1%). Patients were exposed to a wide range of systemic antifungal agents during the period of aplasia, as detailed in Table 2 .
A total of 9 cases of invasive aspergillosis (3 proven and 6 probable) were diagnosed over the 3-year study period, for a calculated cumulative incidence of 8.9% (95% confidence interval [CI] 4.2%-16.2%). The incidence increased to 10.0% (95% CI 4.7%-18.1%) when the 11 patients who received posaconazole prophylaxis were excluded from the analysis. Table 3 details the clinical characteristics of the 9 proven and probable cases of invasive aspergillosis. Pulmonary disease was observed in all 9 patients, 8 of whom underwent fibreoptic bronchoscopy with bronchoalveolar lavage. One patient, a 66-year-old woman (patient 1), experienced disseminated infection with positive histopathologic f indings and growth of Aspergillus fumigatus complex in skin lesions. The median age at diagnosis was 57 (IQR 53-58) years, and the ratio of men to women was 4:5. In 7 cases (78%), invasive aspergillosis occurred after the first course of remission-induction chemotherapy, and the remaining 2 cases (22%) were diagnosed during the second course of chemotherapy. Acute myeloid leukemia was the underlying hematologic malignancy in 7 patients (78%). Invasive aspergillosis was diagnosed at a median of 19 (range 11-34) days after initiation of chemotherapy. The lowest absolute neutrophil count was 0 × 10 9 /L in all but 1 patient; the exception was a patient with acute lymphocytic leukemia who never Note: ALL = acute lymphocytic leukemia, AML = acute myeloid leukemia, ANC = absolute neutrophil count, C = caspofungin, Fl = fluconazole, NA = not applicable, PPx = prophylaxis. *Course of remission-induction chemotherapy during which invasive aspergillosis occurred. †Number of days from initiation of chemotherapy until diagnosis of invasive aspergillosis. ‡Histopathology results compatible with invasive aspergillosis (hyphae-associated tissue damage). §Index value refers to optical density. "Lavage" refers to fluid from bronchoalveolar lavage. Values < 0.5 for serum and < 2.0 for lavage fluid are considered negative.
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CMAJ OPEN experienced neutropenia. The median duration of neutropenia was 18 (IQR 13-22) days. Three patients received caspofungin prophylaxis, and the other 6 patients received fluconazole prophylaxis. Aspergillus species were cultured in samples from 4 of the 9 patients. The galactomannan antigen was detected in 8 patients: in bronchoalveolar lavage fluids only (n = 4), serum only (n = 2) or both (n = 2). Detection of galactomannan antigen was the only positive mycologic criterion identified in 4 of the 6 patients with probable invasive aspergillosis. A total of 4 patients died, 2 with proven and 2 with probable invasive aspergillosis. Three of the patients died within 1 year of the diagnosis of invasive aspergillosis. Only 1 death was directly attributable to invasive aspergillosis (patient 1).
Interpretation
In this study, we sought to determine the incidence of invasive aspergillosis among adult patients who underwent remissioninduction chemotherapy for acute leukemia in a Canadian tertiary care centre.
We identified 9 cases of proven or probable invasive aspergillosis following remission-induction chemotherapy during the 3-year study period. One case occurred in 2008, and the other 8 cases were divided evenly between 2009 and 2010, which suggests the absence of an outbreak. No seasonal variation or notable temporal trends were observed. There were no major construction activities around the institution during the study period, and none of the interior renovation projects that took place during these targeted years were located close to the hematology units. Moreover, courses of remission-induction chemotherapy for patients with acute leukemia were administered in individual rooms with positivepressure high-efficiency particulate air filtration. However, even in this setting with low environmental risk, the cumulative incidence of invasive aspergillosis among patients with acute leukemia was 8.9% (95% CI 4.2%-16.2%), higher than some of the values reported in recent studies (Table 4 ). In fact, the incidence of invasive aspergillosis has been highly variable across studies, a reflection of the multiple risk factors that determine its occurrence. 2, 6, 12, 13, 31 For purposes of homogeneity, we excluded from Table 4 any studies that clearly described universal use of posaconazole as first-line prophylaxis. Important heterogeneity among studies dictates caution when generalizing results from one institution to another.
As expected, most cases of invasive aspergillosis in this study (7 of 9 patients [78%]) occurred during the first course of remission-induction chemotherapy, which is considered the highest-risk period for development of invasive fungal disease among patients with acute leukemia. 1, 18, 25, 32 Our study included 10 patients with acute promyelocytic leukemia, all of whom were treated with an all-trans-retinoic acid regimen. All-transretinoic acid is metabolized by cytochrome P450 isoenzymes, including CYP2C9 and CYP3A4. Possible interactions between this agent and fluconazole (CYP2C9 inhibitor), voriconazole (CYP2C9/3A4 inhibitor) and posaconazole (CYP3A4 inhibitor) have been reported, 33-37 but we did not observe any interactions of this type in our patients. The aspergillosis-attributable mortality rate in our study was 11% (1 of 9 patients). Three other patients with acute myeloid leukemia died within 2 years after diagnosis of invasive aspergillosis, for a 2-year global mortality rate of 44% (4 of 9 patients). A recent study reported that the 2-year survival rate among patients with acute myeloid leukemia and invasive aspergillosis was significantly lower than among patients without invasive aspergillosis, even when the rate was adjusted for response to induction chemotherapy. 38 The galactomannan antigen-detection test, in combination with CT of the lung, is an important tool for early recognition of pulmonary aspergillosis, 39 and the performance of galactomannan antigen-detection testing in serum has been studied extensively. 40, 41 However, among the patients in our study, serum galactomannan antigen-detection testing had limited performance. If diagnosis had been based solely on the results of this test, 5 cases of invasive aspergillosis would have been missed. Interestingly, 3 of these 5 patients were receiving caspofungin therapy. Marr and others 42 reported a significant decrease in the sensitivity of galactomannan antigen-detection testing when patients were receiving mould-active antifungal treatment. In our study, bronchoalveolar lavage fluid was more useful than serum for diagnostic assay of galactomannan antigen.
Following the randomized controlled trial by Cornely and colleagues in 2007, 8 subsequent studies showed, in real-life settings, that the incidence of invasive aspergillosis among patients with acute myeloid and lymphocytic leukemia declined after introduction of posaconazole prophylaxis.
9,43-45 Cornely and colleagues 8 reported a 1% incidence of breakthrough invasive aspergillosis among patients with acute myeloid leukemia who received posaconazole prophylaxis, with a relative risk reduction of 0.9. Given the overall incidence of invasive aspergillosis at our centre (8.9%) and the theoretical relative risk reduction with posaconazole prophylaxis (0.9), the number needed to treat to prevent 1 case of invasive aspergillosis is 13 patients.
The burden of invasive aspergillosis, in terms of mortality, morbidity and cost, and the high incidence at our institution prompted us to consider using posaconazole prophylaxis in this high-risk population. Using data from the study by Cornely and colleagues, 8 subsequent researchers have conducted cost-effectiveness analyses of posaconazole prophylaxis. [46] [47] [48] Two of these studies, which were conducted from the perspective of provincial health care systems in Canada, showed that posaconazole prophylaxis was cost-effective. 47, 48 Taking into account these cost-effectiveness analyses and our institution's high incidence of invasive aspergillosis, it appeared reasonable to initiate use of posaconazole prophylaxis as a standard of care for patients with acute myeloid leukemia undergoing remission-induction chemotherapy.
Limitations
Our study had several limitations. First, many of the patients were exposed to 1 or more mould-active antifungal therapies during the period of aplasia. However, because we sought to determine the incidence of invasive aspergillosis in a real-life setting, we did not exclude patients on the basis of exposure to these drugs. Interestingly, proven or probable invasive aspergillosis was not diagnosed in any of the patients who Research CMAJ OPEN received posaconazole prophylaxis. Second, because the data were collected retrospectively, it was difficult to establish, at least for some patients, the clinical indications for antifungal treatment (prophylactic v. empiric) and to confirm that the patients actually received the prescribed medication. Third, we did not determine risk factors for invasive aspergillosis in this population because the small sample size would have impaired the validity of the results. Finally, we conducted our study at a single tertiary care institution, a referral centre for hematology and hematopoietic stem cell transplantation. As such, and given that the incidence of invasive aspergillosis is influenced by many factors, generalizability may be limited.
Conclusion
We determined that the incidence of invasive aspergillosis among adult patients who underwent intensive remission-induction chemotherapy for acute leukemia at our institution was 8.9%
(95% CI 4.2%-16.2%). The number needed to treat to prevent 1 case of invasive aspergillosis would be about 13 patients. These findings triggered the initiation, in 2011, of universal posaconazole prophylaxis for patients with acute myeloid leukemia undergoing remission-induction chemotherapy at our institution. However, many issues remain unresolved regarding this form of prophylaxis, including the performance of serum galactomannan antigen-detection testing and thoracic CT in low-prevalence populations, the impact of chemotherapy-induced gastrointestinal tract disturbances on bioavailability of posaconazole, the need to monitor serum concentration of posaconazole, the indication for empiric antifungal treatment in febrile neutropenia and the treatment of breakthrough invasive aspergillosis in patients who are receiving posaconazole prophylaxis. Prospective surveillance for invasive aspergillosis in patients with acute myeloid leukemia following introduction of universal posaconazole prophylaxis may shed light on some of these issues. Research CMAJ OPEN
